How could we enhance translation of sepsis immunology to inform immunomodulation trials in sepsis?

Critical Care

Volumn 21, Issue 1, 2017, Pages

  Shankar Hari, M ^a,b,c,d  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c King's College London   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Host response; Immunology; Sepsis; Trials

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 7; PLACEBO; BIOLOGICAL MARKER;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; APOPTOSIS; ARTIFICIAL VENTILATION; CONSENSUS DEVELOPMENT; CONTROLLED CLINICAL TRIAL (TOPIC); CONVALESCENCE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LENGTH OF STAY; LETTER; METHODOLOGY; MORTALITY; PATIENT SELECTION; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SEPSIS; T LYMPHOCYTE; TREATMENT OUTCOME; IMMUNOLOGY; INFLAMMATION;

BIOMARKERS; HUMANS; IMMUNOMODULATION; INFLAMMATION; SEPSIS;

EID: 85020032749     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-017-1715-0     Document Type: Letter

References (14)

1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al. The Third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801-10.
2. Medzhitov R, Schneider DS, Soares MP. Disease tolerance as a defense strategy. Science. 2012;335(6071):936-41.
3. Shankar-Hari M, Rubenfeld GD. The use of enrichment to reduce statistically indeterminate or negative trials in critical care. Anaesthesia. 2017;72(5):560-5.
4. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13(12):862-74.
5. Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med. 2014;20(4):195-203.
6. Antonakos N, Tsaganos T, Oberle V, Tsangaris I, Lada M, Pistiki A, Machairas N, Souli M, Bauer M, Giamarellos-Bourboulis EJ. Decreased cytokine production by mononuclear cells after severe gram-negative infections: early clinical signs and association with final outcome. Crit Care. 2017;21(1):48.
7. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman II SD, Kreisel D, Krupnick AS, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306(23):2594-605.
8. Xiao W, Mindrinos MN, Seok J, Cuschieri J, Cuenca AG, Gao H, Hayden DL, Hennessy L, Moore EE, Minei JP, et al. A genomic storm in critically injured humans. J Exp Med. 2011;208(13):2581-90.
9. Davenport EE, Burnham KL, Radhakrishnan J, Humburg P, Hutton P, Mills TC, Rautanen A, Gordon AC, Garrard C, Hill AV, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med. 2016;4(4):259-71.
10. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14(1):R15.
11. Ballman KV. Biomarker: predictive or prognostic? J Clin Oncol. 2015;33(33):3968-71.
12. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, Weber-Carstens S, Hasper D, Keh D, Zuckermann H, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med. 2009;180(7):640-8.
13. van Vught LA, Wiewel MA, Hoogendijk AJ, Frencken JF, Scicluna BP, Klein Klouwenberg PM, Zwinderman AH, Lutter R, Horn J, Schultz MJ, et al. The host response in sepsis patients developing intensive care unit-acquired secondary infections. Am J Respir Crit Care Med. 2017;20. doi: 10.1164/rccm.201606-1225OC. [Epub ahead of print]
14. van Vught LA, Klein Klouwenberg PM, Spitoni C, Scicluna BP, Wiewel MA, Horn J, Schultz MJ, Nurnberg P, Bonten MJ, Cremer OL, et al. Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA. 2016;315(14):1469-79.